Cargando…
Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment
BACKGROUND: Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041003/ https://www.ncbi.nlm.nih.gov/pubmed/36994048 http://dx.doi.org/10.4103/jfmpc.jfmpc_1164_22 |
_version_ | 1784912610662023168 |
---|---|
author | Nazarinasab, Masoumeh Behrouzian, Forouzan Abdi, Leila Sadegh Moghaddam, Amir Ali Sadeghi, Susan |
author_facet | Nazarinasab, Masoumeh Behrouzian, Forouzan Abdi, Leila Sadegh Moghaddam, Amir Ali Sadeghi, Susan |
author_sort | Nazarinasab, Masoumeh |
collection | PubMed |
description | BACKGROUND: Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role. Antidepressants are prescribed as the first line of treatment for patients with depressive disorders. Selective serotonin reuptake inhibitor (SSRI) antidepressants are used to treat MDD and anxiety; however, some patients do not respond to them. Regarding that, magnesium plays a major role in mood regulation; therefore, this study aimed to investigate the role of magnesium supplement in patients with MDD and under an SSRI treatment regimen. METHODS: In this randomized, double-blind controlled trial, 60 patients with major depressive disorders based on the DSM-V diagnosis referred to Golestan Hospital in Ahvaz, Iran, were included. The eligible patients were categorized randomly into two thirty-people groups receiving magnesium (intervention) and placebo (control) along with SSRI for 6 weeks. To evaluate the depression status, the Beck II test was applied. Subjects were examined before and after the intervention. RESULTS: There was no statistically significant difference between the two groups in terms of demographic characteristics (P > 0.05). The mean Beck scores at the beginning of the study and the second week after the intervention were not different between the two groups (P = 0.97, P = 0.56), whereas the mean Beck scores were lower in the intervention group than in the control group in the fourth and sixth weeks after the intervention (P = 0.02 and P = 0.001, respectively). CONCLUSION: Administration of Mg supplement for at least 6 weeks might improve depression symptoms. It can also be considered as a potential adjunct treatment option for MDD patients who are under SSRI treatment. |
format | Online Article Text |
id | pubmed-10041003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-100410032023-03-28 Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment Nazarinasab, Masoumeh Behrouzian, Forouzan Abdi, Leila Sadegh Moghaddam, Amir Ali Sadeghi, Susan J Family Med Prim Care Original Article BACKGROUND: Major depression disorder (MDD) is a mental disorder that affects millions of people worldwide. This disease has negative impacts on quality of life and psychological-related functions. This is a multifactorial disorder; both genetic background and environmental factors have their role. Antidepressants are prescribed as the first line of treatment for patients with depressive disorders. Selective serotonin reuptake inhibitor (SSRI) antidepressants are used to treat MDD and anxiety; however, some patients do not respond to them. Regarding that, magnesium plays a major role in mood regulation; therefore, this study aimed to investigate the role of magnesium supplement in patients with MDD and under an SSRI treatment regimen. METHODS: In this randomized, double-blind controlled trial, 60 patients with major depressive disorders based on the DSM-V diagnosis referred to Golestan Hospital in Ahvaz, Iran, were included. The eligible patients were categorized randomly into two thirty-people groups receiving magnesium (intervention) and placebo (control) along with SSRI for 6 weeks. To evaluate the depression status, the Beck II test was applied. Subjects were examined before and after the intervention. RESULTS: There was no statistically significant difference between the two groups in terms of demographic characteristics (P > 0.05). The mean Beck scores at the beginning of the study and the second week after the intervention were not different between the two groups (P = 0.97, P = 0.56), whereas the mean Beck scores were lower in the intervention group than in the control group in the fourth and sixth weeks after the intervention (P = 0.02 and P = 0.001, respectively). CONCLUSION: Administration of Mg supplement for at least 6 weeks might improve depression symptoms. It can also be considered as a potential adjunct treatment option for MDD patients who are under SSRI treatment. Wolters Kluwer - Medknow 2022-12 2023-01-17 /pmc/articles/PMC10041003/ /pubmed/36994048 http://dx.doi.org/10.4103/jfmpc.jfmpc_1164_22 Text en Copyright: © 2023 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Nazarinasab, Masoumeh Behrouzian, Forouzan Abdi, Leila Sadegh Moghaddam, Amir Ali Sadeghi, Susan Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment |
title | Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment |
title_full | Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment |
title_fullStr | Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment |
title_full_unstemmed | Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment |
title_short | Investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment |
title_sort | investigating the effect of magnesium supplement in patients with major depressive disorder under selective serotonin reuptake inhibitor treatment |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041003/ https://www.ncbi.nlm.nih.gov/pubmed/36994048 http://dx.doi.org/10.4103/jfmpc.jfmpc_1164_22 |
work_keys_str_mv | AT nazarinasabmasoumeh investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment AT behrouzianforouzan investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment AT abdileila investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment AT sadeghmoghaddamamirali investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment AT sadeghisusan investigatingtheeffectofmagnesiumsupplementinpatientswithmajordepressivedisorderunderselectiveserotoninreuptakeinhibitortreatment |